| diabetes type 2 | versus No demonstrated result for efficacy | 3 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Khanolkar, 2008 | gliclazide vs rosiglitazone (add on MET) | | | | | Ristic, 2006 | gliclazide vs nateglinide (add on MET) | | | | | Matthews, 2005 | gliclazide vs pioglitazone (add on MET) | | | |
| Trial | Treatments | Patients | Method |
|---|
| Khanolkar, 2008 | metformin and gliclazide (n=-9) vs. metformin and rosiglitazone (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: 24 weeks | | Ristic, 2006 | gliclazide plus metformin (n=-9) vs. nateglinide plus metformin (n=-9) | | double-blind Sample size: -9/-9 Primary endpoint: FU duration: 52 weeks | | Matthews, 2005 | gliclazide 80 mg o.d. (titrated up to 320 mg (n=313) vs. pioglitazone 15 mg o.d. (titrated up to 45 mg (n=317) | Patients with poorly controlled type 2 diabetes | double-blind Sample size: 313/317 Primary endpoint: FU duration: 52 weeks |
|
